Health Canada
- Status: approved
🇨🇦 Chronic- PF-06480605 150 mg SC Q4W in Canada
Chronic- PF-06480605 150 mg SC Q4W (chronic-pf-06480605-150-mg-sc-q4w) regulatory status in Canada.
Marketing authorisation
Chronic- PF-06480605 150 mg SC Q4W in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in Canada
Frequently asked questions
Is Chronic- PF-06480605 150 mg SC Q4W approved in Canada?
Yes. Health Canada has authorised it.
Who is the marketing authorisation holder for Chronic- PF-06480605 150 mg SC Q4W in Canada?
Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.